Loading
A phase 1/2 trial of Atezolizumab, Bevacizumab, Tiragolumab in hepatocellular carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) is a phase 1/2 interventional study registered as NCT04524871 by Hoffmann-La Roche, with 518 participants planned, started 2020-11-01 and due to reach its primary completion in 2027-07-30. Interventions recorded: Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120. Conditions listed: Advanced Liver Cancers. No results are recorded here; the registry entry is the source.
Shares Tiragolumab, Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Roche / Genentech.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Roche / Genentech, Bevacizumab.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Tiragolumab, Atezolizumab, Roche / Genentech.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Hepatocellular carcinoma.